For the last two days the Food and Drug Administration (FDA) has been holding a hearing in Bethesda, Maryland on new regulations that would tighten control over stem cell treatments. The FDA invited public testimony during the hearing on the regulations that would impact many of the clinics that currently offer unproven therapies The testimony … Continue reading CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
Food and Drug Administration
New approach could help turn back the clock and reverse damage for stroke patients
Stroke is the leading cause of serious, long-term disability in the US. Every year almost 800,000 people suffer from a stroke. The impact on their lives, and the lives of those around them can be devastating. Right now the only treatment approved by the US Food and Drug Administration (FDA) is tissue plasminogen activator or … Continue reading New approach could help turn back the clock and reverse damage for stroke patients
Finally a possible use for your excess fat; using it to fix your arthritic knee
One of the most common questions we get asked at CIRM, almost every other day to be honest, is “are there any stem cell treatments for people with arthritis in their knees?” It’s not surprising. This is a problem that plagues millions of Americans and is one of the leading causes of disability in the … Continue reading Finally a possible use for your excess fat; using it to fix your arthritic knee
Why is a cell therapy that restores sight to the blind against the law?
A lot of people are frustrated with the US Food and Drug Administration (FDA) and its woefully slow process for approving stem cell therapies. That’s one of the reasons why we started the CIRM Stem Cell Champions campaign, to gather as many like-minded supporters of stem cell research as possible and help to change the … Continue reading Why is a cell therapy that restores sight to the blind against the law?
Timing is everything: could CRISPR gene editing push CIRM to change its rules on funding stem cell research?
Talk about timely. When we decided, several months ago, to hold a Standards Working Group (SWG) meeting to talk about the impact of CRISPR, a tool that is transforming the field of human gene editing, we had no idea that our meeting would fall smack in the midst of a flurry of news stories about … Continue reading Timing is everything: could CRISPR gene editing push CIRM to change its rules on funding stem cell research?
If you want to accelerate stem cell therapies then create an Accelerating Center
“You can’t teach fish to fly,” is one of the phrases that our CIRM President & CEO, Randy Mills, likes to throw out when asked why we needed to create new centers to help researchers move their most promising therapies out of the lab and into clinical trials. His point is that many researchers are … Continue reading If you want to accelerate stem cell therapies then create an Accelerating Center
Patients beware: warnings about shady clinics and suspect treatments
Every day we get a call from someone seeking help. Some are battling a life-threatening or life-changing disease. Others call on behalf of a friend or loved one. All are looking for the same thing; a treatment, better still a cure, to ease their suffering. Almost every day we have to tell them the same … Continue reading Patients beware: warnings about shady clinics and suspect treatments
Doing nothing is not OK: A call for change at the FDA
The US Food and Drug Administration (FDA) is caught between a rock and a hard place. And CIRM is going to try and help them get out from under that. As things stand today, if the FDA approves a therapy quickly and a patient later dies from it, then they are widely criticized. If they … Continue reading Doing nothing is not OK: A call for change at the FDA
Why “Right to Try” laws are more feel good than do good
L to R: Don Gibbons, CIRM; Jeanne Loring; Beth Roxland; Aaron Levine In the last few years some 24 states have approved so-called “Right to Try” laws. These are intended to give terminally ill patients faster and easier access to experimental therapies. But a panel of experts at the World Stem Cell Summit in Atlanta … Continue reading Why “Right to Try” laws are more feel good than do good
Call to Action by FDA at World Stem Cell Summit
FDA Deputy Commissioner Dr. Robert Califf talking at the World Stem Cell Summit The World Stem Cell Summit annual conference in Atlanta kicked off today with a clarion call from Dr. Robert Califf, the Deputy Commissioner for the Food and Drug Administration. He told the audience: “We want you to accelerate translation to produce safe … Continue reading Call to Action by FDA at World Stem Cell Summit
The Stem Cellar 